InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
3
T+90 hit rate
100%
T+90 mean return
+17.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by THOMAS PAUL, Director. Officer active across 3 companies, notably Surgalign Holdings, INC.. Cumulatively, 18 reports have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €759k. Activity tracked since 7 May 2021. The latest transaction was disclosed on 1 September 2024 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
18,867 sharesCommon StockSEC:0000805928-26-000078:0
2,875 sharesCommon StockSEC:0000805928-24-000131:0
11,904 shares0Common StockSEC:0000805928-24-000117:0
10,653 sharesCommon StockSEC:0000805928-24-000097:0
6,459 shares0Common StockSEC:0000805928-23-000058:0
6,357 sharesCommon Stock, $.01 par valueSEC:0001415889-22-013000:0
1,000 shares@ US$379.3850.6% of flowCommon Stock, $.01 par valueSEC:0001415889-22-011063:0
22,857 shares0Common StockSEC:0001209191-22-046168:0
681 shares0Common Stock, $.01 par valueSEC:0001415889-22-008531:0
3,036 shares0Common StockSEC:0000805928-22-000069:0
663 shares@ US$330.7750.0% of flowCommon Stock, $.01 par valueSEC:0001179110-21-008306:0
663 shares@ US$330.7724.7% of flowCommon Stock, $.01 par valueSEC:0001179110-21-008306
625 shares0Common Stock, $.01 par valueSEC:0001179110-21-008178:0
625 shares0Common Stock, $.01 par valueSEC:0001179110-21-008178
72,254 shares0Common StockSEC:0001209191-21-045030
72,254 shares0Common StockSEC:0001209191-21-045030:0
57,803 shares0Common StockSEC:0001209191-21-031336:0
57,803 shares0Common StockSEC:0001209191-21-031336
18 of 18 declarations
About THOMAS PAUL
Paul Thomas serves as a Director of Surgalign Holdings, Inc., Abiomed Inc., and Axogen, Inc. In this role, he participates in the governance of these companies and in making strategic decisions. His experience in the medical sector is valuable in guiding these companies towards innovation.
